DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0152283 A1 Gant (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0152283 A1 Gant (43) Pub US 20100152283A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0152283 A1 Gant (43) Pub. Date: Jun. 17, 2010 (54) TETRAHYDROCANNABINOL Publication Classification MODULATORS OF CANNABINOD (51) Int. Cl. RECEPTORS A63L/352 (2006.01) C07D 3II/80 (2006.01) (52) U.S. Cl. ......................................... 514/454; 549/390 (75) Inventor: Thomas G. Gant, Carlsbad, CA (US) (57) ABSTRACT The present invention relates to new tetrahydrocannabinol modulators of cannabinoid receptors, pharmaceutical com Correspondence Address: positions thereof, and methods of use thereof. GLOBAL PATENT GROUP - APX 10411 Clayton Road, Suite 304 ST. LOUIS, MO 63131 (US) Formula I (73) Assignee: AUSPEX PHARMACEUTICALS, INC., Vista, CA (US) (21) Appl. No.: 12/640,107 (22) Filed: Dec. 17, 2009 Related U.S. Application Data (60) Provisional application No. 61/138,517, filed on Dec. 17, 2008. US 2010/0152283 A1 Jun. 17, 2010 TETRAHYDROCANNABINOL abdominal pain, nausea, Vomiting, amnesia, anxiety, ataxia, MODULATORS OF CANNABINOD confusion, depersonalization, dizziness, euphoria, hallucina RECEPTORS tion, paranoid reaction, Somnolence, abnormal thinking, con junctivitis, hypotension, diarrhea, fecal incontinence, myal gia, depression, nightmares, speech difficulties, tinnitus, and 0001. This application claims the benefit of priority of vision difficulties. U.S. provisional application No. 61/138,517, filed Dec. 17, 2008, the disclosure of which is hereby incorporated by ref DEUTERIUM KINETIC ISOTOPE EFFECT erence as if written herein in its entirety. 0005. In order to eliminate foreign substances such as 0002 Disclosed herein are new tetrahydrocannabinol therapeutic agents, the animal body expresses various compounds, pharmaceutical compositions made thereof, and enzymes, such as the cytochrome Paso enzymes (CYPs), methods to modulate cannabinoid receptor activity in a Sub esterases, proteases, reductases, dehydrogenases, and ject are also provided for, for the treatment of disorders such monoamine oxidases, to react with and convert these foreign as chemotherapy-induced emesis, pain, neuropathic pain, Substances to more polar intermediates or metabolites for multiple Sclerosis, spasticity, Alzheimer's disease, nausea, renal excretion. Such metabolic reactions frequently involve Vomiting, affective disorders, anorexia nervosa, dementia, the oxidation of a carbon-hydrogen (C H) bond to either a major depressive disorder, cachexia, HIV wasting syndrome, carbon-oxygen (C-O) or a carbon-carbon (C-C) JU-bond. Tourette's syndrome, and emesis. The resultant metabolites may be stable or unstable under 0003 Dronabinol (Marinol R, THC, delta-9-tetrahydro physiological conditions, and can have substantially different cannabinol, delta-9-THC, SP-104, ElevatR, CompassiaR), pharmacokinetic, pharmacodynamic, and acute and long CAS # 1972-08-3), (-)-(6aR,10aR)-6,6,9-trimethyl-3-pen term toxicity profiles relative to the parent compounds. For tyl-6a, 7.8.10a-tetrahydro-6H-benzocchromen-1-ol, is a most drugs, such oxidations are generally rapid and ulti cannabinoid receptor agonist. Dronabinol is commonly pre mately lead to administration of multiple or high daily doses. scribed for the treatment of chemotherapy-induced emesis, 0006. The relationship between the activation energy and cachexia, emesis, and anorexia nervosa (Drug Report for the rate of reaction may be quantified by the Arrhenius equa Dronabinol, Thompson Investigational Drug Database (Aug. tion, k=Ae'. The Arrhenius equation states that, at a 12, 2008); Beal et al., J. Pain Symptom Management 1995, given temperature, the rate of a chemical reaction depends 10(2), 89-97: Meiri et al., Curr. Med. Res. Opin. 2007, 23(3), exponentially on the activation energy (E). 533-43; Struwe et al., Ann. Pharmacother: 1993, 27, 827-31; 0007. The transition state in a reaction is a short lived state and Volicer et al., Int. J. Geriatric Psych. 1997, 12,913-19). along the reaction pathway during which the original bonds Dronabinol has also shown promise in treating pain, neuro have stretched to their limit. By definition, the activation pathic pain, multiple Sclerosis, spasticity, Alzheimer's dis energy E for a reaction is the energy required to reach the ease, nausea; Vomiting, affective disorders, dementia, major transition state of that reaction. Once the transition state is depressive disorder, HIV wasting syndrome, Tourette's syn reached, the molecules can either revert to the original reac drome, asthma, and glaucoma (Drug Report for Dronabinol, tants, or form new bonds giving rise to reaction products. A Thompson Investigational Drug Database (Aug. 12, 2008); catalyst facilitates a reaction process by lowering the activa Ashton et al., Curr. Opin. Invest. Drugs 2008, 9(1), 65-75; tion energy leading to a transition state. Enzymes are Baker et al., Nature 2000, 404, 84-87; Beal et al., J. Pain examples of biological catalysts. Symptom Management 1995, 10(2), 89-97: Rice, Curr: Opin. 0008 Carbon-hydrogen bond strength is directly propor Invest. Drugs 2001, 203), 399-414; Struwe et al., Ann. Phar tional to the absolute value of the ground-state vibrational macother: 1993,27,827-31; and Volicer et al., Int. J. Geriatric energy of the bond. This vibrational energy depends on the Psych. 1997, 12,913-19). mass of the atoms that form the bond, and increases as the mass of one or both of the atoms making the bond increases. Since deuterium (D) has twice the mass of protium (H), a Dronabinol C-D bond is stronger than the corresponding C–H bond. If a C-H bond is broken during a rate-determining step in a chemical reaction (i.e. the step with the highest transition state energy), then Substituting a deuterium for that protium will cause a decrease in the reaction rate. This phenomenon is known as the Deuterium Kinetic Isotope Effect (DKIE). The magnitude of the DKIE can be expressed as the ratio between the rates of a given reaction in which a C H bond is broken, and the same reaction where deuterium is substituted for protium. The DKIE can range from about 1 (no isotope effect) to very large numbers, such as 50 or more. Substitution of 0004 Dronabinol is subject to CYP2C9-, CYP2C19-, and tritium for hydrogen results in yet a stronger bond than deu CYP3A4-mediated oxidation of the allylic methyl and meth terium and gives numerically larger isotope effects. ylene groups to form 11-hydroxy-delta-9-tetrahydrocannab I0009 Deuterium (H or D) is a stable and non-radioactive inol, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, isotope of hydrogen which has approximately twice the mass and 8-hydroxy-delta-9-tetrahydrocannabinol (Perez-Reyes, of protium (H), the most common isotope of hydrogen. J. Clin. Pharmacol. 1981, 21, 178S-189S; and Wall et al., Deuterium oxide (DO or “heavy water) looks and tastes like Clin. Pharmacol. Ther: 1983,34(3), 352-63). Adverse effects HO, but has different physical properties. associated with dronabinol administration include: asthenia, 0010 When pure DO is given to rodents, it is readily palpitations, tachycardia, Vasodilation, facial flushing, absorbed. The quantity of deuterium required to induce tox US 2010/0152283 A1 Jun. 17, 2010 icity is extremely high. When about 0-15% of the body water ings. Various deuteration patterns can be used to (a) reduce or has been replaced by DO, animals are healthy but are unable eliminate unwanted metabolites, (b) increase the half-life of to gain weight as fast as the control (untreated) group. When the parent drug, (c) decrease the number of doses needed to about 15-20% of the body water has been replaced with D.O. achieve a desired effect, (d) decrease the amount of a dose the animals become excitable. When about 20-25% of the needed to achieve a desired effect, (e) increase the formation body water has been replaced with DO, the animals become of active metabolites, if any are formed, (f) decrease the so excitable that they go into frequent convulsions when production of deleterious metabolites in specific tissues, and/ stimulated. Skin lesions, ulcers on the paws and muzzles, and or (g) create a more effective drug and/or a safer drug for necrosis of the tails appear. The animals also become very polypharmacy, whether the polypharmacy be intentional or aggressive. When about 30% of the body water has been not. The deuteration approach has the strong potential to slow replaced with DO, the animals refuse to eat and become the metabolism of dronabinol and attenuate interpatient vari comatose. Their body weight drops sharply and their meta ability. bolic rates drop far below normal, with death occurring at 0014 Novel compounds and pharmaceutical composi about 30 to about 35% replacement with D.O.The effects are tions, certain of which have been found to modulate cannab reversible unless more than thirty percent of the previous inoid receptors have been discovered, together with methods body weight has been lost due to D.O. Studies have also of synthesizing and using the compounds, including methods shown that the use of DO can delay the growth of cancer cells for the treatment of cannabinoid receptor-mediated disorders and enhance the cytotoxicity of certain antineoplastic agents. in a patient by administering the compounds as disclosed 0011 Deuteration of pharmaceuticals to improve pharma herein. cokinetics (PK), pharmacodynamics (PD), and toxicity pro 0015. In certain embodiments of the present invention, files has been demonstrated previously with some classes of compounds have structural Formula I: drugs. For example, the DKIE was used to decrease the hepa totoxicity of halothane, presumably by limiting the produc tion of reactive species such as trifluoroacetylchloride. How (I) ever, this method may not be applicable to all drug classes. For example, deuterium incorporation can lead to metabolic Switching. Metabolic Switching occurs when Xenogens, sequestered by Phase I enzymes, bind transiently and re-bind in a variety of conformations prior to the chemical reaction (e.g., oxidation). Metabolic switching is enabled by the rela tively vast size of binding pockets in many Phase I enzymes and the promiscuous nature of many metabolic reactions.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T (51) International Patent Classification: (72) Inventors; and A61K 31/352 (2006.01) A61P 25/24 (2006.01) (75) Inventors/Applicants (for US only): LETENDRE, Peter A61K 9/48 (2006.01) A61P 25/22 (2006.01) [US/US]; 2389 Indian Peaks Trail, Lafayette, Colorado A61K 9/20 (2006.01) A61P 25/00 (2006.01) 80026 (US). CARLEY, David [US/US]; 2457 Pioneer Rd., Evanston, Illinois 60201 (US). (21) International Application Number: PCT/US201 1/061490 (74) Agents: FEDDE, Kenton et al; 18325 AUenton Woods Ct, Wildwood, Missouri 63069 (US). (22) International Filing Date: 18 November 201 1 (18.1 1.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/415,33 1 18 November 2010 (18. 11.2010) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): PIER MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PHARMACEUTICALS [US/US]; 901 Front St., Suite OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 201, Louisville, Colorado 80027 (US).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Treatment of Depression Magdalena Burat* , Ewa Gibula-Tarlowska , Ewa Kedzierska
    DOI: 10.2478/cipms-2020-0036 Curr. Issues Pharm. Med. Sci., Vol. 33, No. 4, Pages 177-183 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Different molecular targets, one purpose – treatment of depression Magdalena Burat* , Ewa Gibula-Tarlowska , Ewa Kedzierska Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland ARTICLE INFO ABSTRACT Received 12 January 2020 Although vast scientific progress has been made, the current pharmacotherapy Accepted 04 December 2020 of depression is still not fully effective. In adults, depressive disorders are among the Keywords: most common diseases in industrialized countries, impact upon all aspects of family and depression, working life and significantly disturb social functioning. Moreover, increasingly, they antidepressants, affect children and teenagers. atypical mechanisms, novel strategies. Depressive disorders have a complex etiology. This includes a number of mechanisms that are not yet fully understood. Therefore, the current review concentrates on bringing to the foreground the many molecular areas involved in occurrence of this disease. The work highlights the notion that depression has a complex pharmacology and inevitably requires the adoption of individual pharmacotherapy. This manuscript concentrates on currently used drugs drawn from diverse therapeutic groups and presents new promising targets for the treatment of depression. This is a particularly important issue due to the continuous lack of effective therapy and the constant search for new drugs and molecular targets for its treatment. INTRODUCTION Depression and its accompanying symptoms are a – especially of monoamines, such as serotonin (5-HT), common cause of disability in the world.
    [Show full text]
  • An Open-Label, Multicenter, Expanded Access Study Of
    Clinical Development INC424 (ruxolitinib) Protocol CINC424A2401 / NCT01493414 An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post- essential thrombocythemia myelofibrosis (PET-MF) Authors Document type Amended Protocol Version EUDRACT number 2010-024473-39 Version number 05 (Clean) Development phase IIIB Document status Final Release date 21-Mar-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Novartis Confidential Page 2 Amended Protocol Version 05 (Clean) Protocol No. CINC424A2401 Table of contents Table of contents .................................................................................................................2 List of figures ......................................................................................................................6 List of tables ........................................................................................................................6 List of abbreviations ............................................................................................................7 Glossary of terms...............................................................................................................10 Amendment 5 ....................................................................................................................11 Oncology clinical study protocol synopsis........................................................................39
    [Show full text]
  • (MONALEESA-3): a Randomized Double-Blind, Placebo-Controlled
    Clinical Development LEE011 (ribociclib) Protocol CLEE011F2301 / NCT02422615 MONALEESA-3: A randomized double-blind, placebo- controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment Authors Document type Amended Protocol Version (Clean) EUDRACT number 2015-000617-43 Version number 02 (Amended Protocol) Development phase III Document status Final Release date 28-Jul-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Template version 17-Nov-2014 Novartis Confidential Page 2 Amended Protocol Version 02 (Clean) Protocol No. CLEE011F2301 Table of contents Table of contents ................................................................................................................. 2 List of figures ...................................................................................................................... 6 List of tables ........................................................................................................................ 6 List of abbreviations ............................................................................................................ 8 Glossary of terms ............................................................................................................... 11 Amendment 2 (28-Jul-2016) ............................................................................................
    [Show full text]
  • WO 2011/092290 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date ι 4 August 2011 (04.08.2011) WO 201 1/092290 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 491/048 (2006.01) A61P 25/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4162 (2006.01) A61P 39/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/EP20 11/05 1221 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 28 January 201 1 (28.01 .201 1) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/300,231 1 February 2010 (01 .02.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): NO- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (CH).
    [Show full text]